For pharmaceutical manufacturers and international supply partners, pharmacovigilance is relevant to the broader lifecycle of a medicine. It connects information from healthcare practice with the ongoing assessment of a product\u2019s safety profile and the management of potential risks after marketing.<\/p>\n
Vietnam\u2019s National Pharmacovigilance Conference: Key Priorities<\/h4>\n
The 2026 conference was held under the theme \u201cPharmacovigilance Practice in Vietnam: Digital Transformation, Integration and Development.\u201d<\/em> Its programme addressed developments in pharmacovigilance practice, digital transformation in line with international standards, risk identification, patient-specific considerations and the safe use of high-risk medicines.<\/p>\n The conference was organised through collaboration between the National DI&ADR Centre and the regional centre based at Cho Ray Hospital. Its online format enabled healthcare professionals interested in clinical pharmacy and pharmacovigilance to participate.<\/p>\n These discussions reflect the importance of strengthening the way medicine safety information is collected, assessed, communicated and used in healthcare practice<\/p>\n . Digital transformation can support the management and analysis of medicine safety information. Better structured data and more effective information exchange may help relevant professionals identify patterns and assess potential safety signals.<\/p>\n However, digital tools do not replace clinical assessment, scientific judgement or appropriate follow-up. The value of pharmacovigilance depends on the quality of the information collected, the methods used to evaluate it and the actions taken when a potential risk is identified.<\/p>\n The conference\u2019s focus on digital transformation therefore provides a useful perspective on the continuing development of Vietnam\u2019s medicine safety infrastructure.<\/p>\n For international pharmaceutical buyers, evaluating a manufacturer involves more than reviewing its manufacturing facilities and quality certifications. Understanding how product safety is considered throughout the medicine lifecycle is also relevant.<\/p>\n Pharmacovigilance supports the monitoring of suspected adverse drug reactions and the evaluation of potential risks associated with medicines in clinical use. When relevant safety information becomes available, appropriate assessment and follow-up help inform decisions about the product\u2019s benefit\u2013risk profile.<\/p>\n Several aspects are important to this process:<\/p>\n Pharmacovigilance is therefore an important part of pharmaceutical quality accountability. It complements, rather than replaces, good manufacturing practices, quality control and other applicable quality-system requirements.<\/p>\n For international partners, these functions should be evaluated through appropriate documentation, regulatory evidence and discussions with the manufacturer. Attendance at an industry conference alone does not establish the maturity or effectiveness of a company’s pharmacovigilance system.<\/p>\n International pharmaceutical partnerships operate across different regulatory environments, healthcare systems and reporting practices. The management of medicine safety information is consequently relevant to both manufacturers and their partners.<\/p>\n Digital tools may help improve data handling and information exchange, while consistent reporting and appropriate assessment remain essential to the interpretation of safety information.<\/p>\n For importers and distributors, practical questions include how suspected adverse drug reactions should be communicated, which parties are responsible for reporting, how safety information is escalated and what local regulatory requirements apply.<\/p>\n These responsibilities should be clearly defined for each market and product. Regulatory obligations are not identical across all countries, and partners should confirm the applicable requirements with the relevant authorities and qualified regulatory professionals.<\/p>\n For manufacturers in Vietnam serving international markets, engagement with developments in the national pharmacovigilance environment can provide useful industry context. It does not, by itself, demonstrate compliance with every importing country’s requirements.<\/p>\n![\"Vietnam\u2019s](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/1-2-640x427.jpg\")
<\/p>\nWhy digital transformation matters in pharmacovigilance<\/h4>\n
![\"Why](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/3-1-640x321.jpg\")
<\/p>\nPharmacovigilance and Pharmaceutical Manufacturing Quality<\/h4>\n
\n
Digital Transformation and Its Relevance to International Supply Partners
![\"Digital](\"https:\/\/vinphaco.net\/wp-content\/uploads\/2026\/10\/2-3-640x427.jpg\")
<\/h4>\nVINPHACO and the Broader Pharmaceutical Quality Perspective<\/h4>\n